Linton-Romir, N. and Rothschedl, E. and Geiger-Gritsch, S. (2025): Catumaxomab (Korjuny®) for the treatment of malignant ascites. Fact Sheet Nr. 196.

Rothschedl, E. and Linton-Romir, N. (2025): Tislelizumab (Tevimbra®) with chemotherapy for the first-line treatment of HER-2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma. Fact Sheet Nr. 199.

Rothschedl, E. and Linton-Romir, N. (2025): Tislelizumab (Tevimbra®) with etoposide and platinum chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer. Fact Sheet Nr. 225.

Rothschedl, E. and Linton-Romir, N. (2025): Tislelizumab (Tevimbra®) with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer. Fact Sheet Nr. 241.